TuHURA Biosciences Files 8-K

Ticker: HURA · Form: 8-K · Filed: Mar 18, 2025 · CIK: 1498382

Sentiment: neutral

Topics: disclosure, financials, regulatory

TL;DR

TuHURA Biosciences filed an 8-K on 3/18/25 - check for updates.

AI Summary

TuHURA Biosciences, Inc. filed an 8-K on March 18, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Kintara Therapeutics, Inc., is incorporated in Nevada and headquartered in Tampa, Florida.

Why It Matters

This filing provides important updates and disclosures for investors regarding TuHURA Biosciences, Inc., including financial information and regulatory compliance.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, which typically contains standard disclosures and does not inherently indicate new risks.

Key Numbers

Key Players & Entities

FAQ

What specific information is being disclosed under Regulation FD?

The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the header information.

What financial statements and exhibits are included in this filing?

The filing states that Financial Statements and Exhibits are included, but their specific content is not detailed in the header.

When was TuHURA Biosciences, Inc. previously known as Kintara Therapeutics, Inc.?

The filing indicates that the former company name was Kintara Therapeutics, Inc., but does not specify the date of the name change in the provided header.

What is the principal executive office address for TuHURA Biosciences, Inc.?

The principal executive offices are located at 10500 University Center Dr., Suite 110, Tampa, Florida 33612.

What is the SIC code for TuHURA Biosciences, Inc.?

The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on March 18, 2025 regarding TuHURA Biosciences, Inc./NV (HURA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing